163 related articles for article (PubMed ID: 20824395)
1. Decreased brain FDG uptake in patients with extensive non-Hodgkin's lymphoma lesions.
Hanaoka K; Hosono M; Shimono T; Usami K; Komeya Y; Tsuchiya N; Yamazoe Y; Ishii K; Tatsumi Y; Sumita M
Ann Nucl Med; 2010 Dec; 24(10):707-11. PubMed ID: 20824395
[TBL] [Abstract][Full Text] [Related]
2. Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Hanaoka K; Hosono M; Usami K; Tatsumi Y; Yamazoe Y; Komeya Y; Tsuchiya N; Ishii K; Sumita M
Nucl Med Commun; 2011 Aug; 32(8):678-83. PubMed ID: 21499162
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
Zhang Q; Tian T; Wang L; Qiu H; Li D
Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
[TBL] [Abstract][Full Text] [Related]
4. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
[TBL] [Abstract][Full Text] [Related]
5. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Eur J Haematol; 2015 Jul; 95(1):83-9. PubMed ID: 25537478
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.
Kajáry K; Tőkés T; Dank M; Kulka J; Szakáll S; Lengyel Z
Nucl Med Commun; 2015 Jan; 36(1):28-37. PubMed ID: 25299471
[TBL] [Abstract][Full Text] [Related]
7. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.
Heckmann MB; Totakhel B; Finke D; Anker MS; Müller-Tidow C; Haberkorn U; Katus HA; Lehmann LH
ESC Heart Fail; 2019 Aug; 6(4):824-829. PubMed ID: 31278857
[TBL] [Abstract][Full Text] [Related]
9. Patterns of FDG uptake in pancreatic non-Hodgkin's lymphoma lesions.
Dong A; Cui Y; Gao L; Wang Y; Zuo C; Yang J
Abdom Imaging; 2014 Feb; 39(1):175-86. PubMed ID: 24136586
[TBL] [Abstract][Full Text] [Related]
10. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
11. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
[TBL] [Abstract][Full Text] [Related]
13. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
14. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
15. Quantification of local tumor response to fractionated radiation therapy for non-Hodgkin lymphoma using weekly 18F-FDG PET/CT imaging.
Keller H; Goda JS; Vines DC; Lockwood G; Tsang R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):850-8. PubMed ID: 19515502
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
17. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
18. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography.
Khandani AH; Dunphy CH; Meteesatien P; Dufault DL; Ivanovic M; Shea TC
Nucl Med Commun; 2009 Aug; 30(8):594-601. PubMed ID: 19536037
[TBL] [Abstract][Full Text] [Related]
19. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.
Phongkitkarun S; Varavithya V; Kazama T; Faria SC; Mar MV; Podoloff DA; Macapinlac HA
World J Gastroenterol; 2005 Dec; 11(46):7284-9. PubMed ID: 16437629
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of 18F-FDG PET/CT for evaluating response of ocular adnexal lymphoma to treatment.
Fujii H; Tanaka H; Nomoto Y; Harata N; Oota S; Isogai J; Yoshida K
Medicine (Baltimore); 2018 Apr; 97(17):e0543. PubMed ID: 29703034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]